PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1568638
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1568638
Pet Monoclonal Antibodies Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
The Global Pet monoclonal antibodies market size is anticipated to grow at 14.2% CAGR between 2024 and 2032 driven by the increasing prevalence of chronic and infectious diseases in pets, which necessitates advanced diagnostic and therapeutic solutions. Monoclonal antibodies offer targeted and effective treatment options for various conditions, such as cancer, autoimmune disorders, and infectious diseases in animals. As per reports, around 1 in 4 dogs and 1 in 5 cats suffer from cancer globally.
R and D efforts aimed at creating more effective and safer antibody therapies expand the range of available treatments, enhancing their appeal to veterinarians and pet owners. The support from veterinary pharmaceutical companies, along with regulatory approvals and increased funding for veterinary research, further accelerates market growth.
The overall industry is divided into animal, application, end user, and region.
Based on animal, the pet monoclonal antibodies market size from the cats segment is poised to grow between 2024 and 2032. This is backed by increasing recognition and treatment of feline-specific health conditions using advanced therapies. Cats are prone to various illnesses, including cancers, autoimmune diseases, and viral infections, and can benefit significantly from targeted monoclonal antibody treatments.
In terms of end user, the pet monoclonal antibodies market from the veterinary clinics segment is set to witness a significant CAGR from 2024 to 2032. This is owing to the increasing adoption of advanced diagnostic and therapeutic technologies in clinical settings. Veterinary clinics are increasingly incorporating monoclonal antibodies into their treatment protocols for various conditions, such as cancer, autoimmune diseases, and chronic infections in pets.
Asia Pacific monoclonal antibodies industry is expected to accrue notable expansion from 2024 to 2032 driven by the increasing pet ownership and rising awareness of advanced veterinary care in the region. As more people invest in their pets' health and well-being, there is a growing demand for effective and targeted treatments for chronic and complex diseases, such as cancers and autoimmune disorders.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising prevalence of chronic disease in pets
- 3.2.1.2 Growing advancement in targeted therapies
- 3.2.1.3 Increasing R and D investment and activities
- 3.2.1.4 Growing pet ownership and spending
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 Adverse effects of the treatment
- 3.2.2.2 Regulatory challenges
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Future market trends
- 3.6 Pipeline analysis
- 3.7 Pet population, by country
- 3.8 Porter's analysis
- 3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Animal, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Dogs
- 5.3 Cats
Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Dermatology
- 6.3 Osteoarthritis
- 6.4 Cancer
- 6.5 Other applications
Chapter 7 Market Estimates and Forecast, By End-User, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Veterinary hospitals
- 7.3 Veterinary clinics
- 7.4 Academics and research institutes
Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 The Netherlands
- 8.3.7 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
- 8.6 Middle East and Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
- 9.1 Ceva Sante Animale
- 9.2 Boehringer Ingelheim International GmbH
- 9.3 Elanco Animal Health
- 9.4 Merck Animal Health
- 9.5 Sanofi
- 9.6 Vetigenics
- 9.7 Zoetis Inc.
